Browse Posters

Efficacy and Safety of Lumateperone versus Atypical Antipsychotics as Adjunctive Therapy in Major Depressive Disorder: A Pooled-Dose Network Meta-Analysis Andrew J. Cutler, MD: SUNY Upstate Medical University, Syracuse, NY, USA;Anaïs Lemyre, PhD: Analysis Group ULC, Montreal, QC, Canada;Qiaoyi Zhang, MD, PhD: Johnson & Johnson, Raritan, NJ, USA;Carol Mao, MS, MBA: Johnson & Johnson, Raritan, NJ, USA;Todor I. Totev, MBA: Analysis Group, Inc., Boston, MA, USA;Marjolaine Gauthier-Loiselle, PhD: Analysis Group ULC, Montreal, QC, Canada;Yuji...
Potential Persistence or Exacerbation of Postpartum Obsessive-Compulsive Disorder Associated with Oral Contraceptive Use: A Case Report. Thomas Sim, DO: Virtua, New Jersey
Neuropsychiatric Burden and Tau/Aß42 Biomarker Elevation Identify High-Risk Alzheimer’s Disease Converters Within a Major Depressive Disorder Cohort Sylvester Orimaye, PhD, MPH, University of Health Sciences and Pharmacy in St. Louis, MO
Clinical Analysis of 50 Patients at IAM (Institute of Attention & Mood) in Huntsville & Madison, Al through use of Conners CPT-3 in the Diagnostic Evaluation of ADHD STEPHANIE BLUME, CRNP, PMHNP-BC Associate Clinical Director, Institute of Attention and Mood (IAM);Gagan Dhaliwal, MD Clinical Director Affiliation: Institute of Attention & Mood (IAM)
Optimizing PMHNP Integration in Maximum-Security Forensic Psychiatry: An Evidence-Informed Framework for Competency Restoration, Safety, and Systems Outcomes Jeffrey Dobbins, DNP, APRN, PMHNP, CNEcl, Susan Piper, DNP, APRN, PMHNP, Lisa Barnes, DNP, APRN, PMHNP, CNEcl
Efficacy of Centanafadine in Children and Adolescents With ADHD and High Baseline Emotional Dysregulation: A Post Hoc Analysis of Two Phase 3 Trials Caroline L. Ward, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Zhen Zhang, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Greg Parks, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ: Judy v...
Efficacy of Centanafadine in Children and Adolescents With ADHD and High Baseline Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials Timothy E. Wilens, MD: Division of Child and Adolescent Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Ann C. Childress, MD: Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV; Zhen Zhang, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercializ...
Treatment Outcomes With Centanafadine in Preschool-Aged Children (4–5 Years) With ADHD: Results From a Phase 3 Randomized Clinical Trial Caroline L. Ward, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Ann C. Childress, MD: Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV; Dorothee Oberdhan, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Ro...
Safety and Tolerability of Once-Daily Extended-Release Centanafadine for the Treatment of ADHD in Children Aged 4–5 Years: Results From a Phase 3 Randomized Clinical Trial Osman Turkoglu, MD, CCRC: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Caroline L. Ward, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Ann C. Childress, MD: Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV
Implementation of an intranasal esketamine service on an adult inpatient voluntary psychiatry unit Megan Maroney PharmD, BCPP, FAAPP, Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey and Monmouth Medical Center, Long Branch, NJ; Laura Borque, MSN, RN, PMH-BC, NPD-BC Monmouth Medical Center, Long Branch, NJ
1 2 3 4 5

Efficacy and Safety of Lumateperone versus Atypical Antipsychotics as Adjunctive Therapy in Major Depressive Disorder: A Pooled-Dose Network Meta-Analysis

Andrew J. Cutler, MD: SUNY Upstate Medical University, Syracuse, NY, USA;Anaïs Lemyre, PhD: Analysis Group ULC, Montreal, QC, Canada;Qiaoyi Zhang, MD, PhD: Johnson & Johnson, Raritan, NJ, USA;Carol Mao, MS, MBA: Johnson & Johnson, Raritan, NJ, USA;Todor I. Totev, MBA: Analysis Group, Inc., Boston, MA, USA;Marjolaine Gauthier-Loiselle, PhD: Analysis Group ULC, Montreal, QC, Canada;Yuji...

Potential Persistence or Exacerbation of Postpartum Obsessive-Compulsive Disorder Associated with Oral Contraceptive Use: A Case Report.

Thomas Sim, DO: Virtua, New Jersey

Neuropsychiatric Burden and Tau/Aß42 Biomarker Elevation Identify High-Risk Alzheimer’s Disease Converters Within a Major Depressive Disorder Cohort

Sylvester Orimaye, PhD, MPH, University of Health Sciences and Pharmacy in St. Louis, MO

Clinical Analysis of 50 Patients at IAM (Institute of Attention & Mood) in Huntsville & Madison, Al through use of Conners CPT-3 in the Diagnostic Evaluation of ADHD

STEPHANIE BLUME, CRNP, PMHNP-BC Associate Clinical Director, Institute of Attention and Mood (IAM);Gagan Dhaliwal, MD Clinical Director Affiliation: Institute of Attention & Mood (IAM)

Optimizing PMHNP Integration in Maximum-Security Forensic Psychiatry: An Evidence-Informed Framework for Competency Restoration, Safety, and Systems Outcomes

Jeffrey Dobbins, DNP, APRN, PMHNP, CNEcl, Susan Piper, DNP, APRN, PMHNP, Lisa Barnes, DNP, APRN, PMHNP, CNEcl

Efficacy of Centanafadine in Children and Adolescents With ADHD and High Baseline Emotional Dysregulation: A Post Hoc Analysis of Two Phase 3 Trials

Caroline L. Ward, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Zhen Zhang, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Greg Parks, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ: Judy v...

Efficacy of Centanafadine in Children and Adolescents With ADHD and High Baseline Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials

Timothy E. Wilens, MD: Division of Child and Adolescent Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Ann C. Childress, MD: Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV; Zhen Zhang, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercializ...

Treatment Outcomes With Centanafadine in Preschool-Aged Children (4–5 Years) With ADHD: Results From a Phase 3 Randomized Clinical Trial

Caroline L. Ward, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Ann C. Childress, MD: Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV; Dorothee Oberdhan, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Ro...

Safety and Tolerability of Once-Daily Extended-Release Centanafadine for the Treatment of ADHD in Children Aged 4–5 Years: Results From a Phase 3 Randomized Clinical Trial

Osman Turkoglu, MD, CCRC: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Caroline L. Ward, PhD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Taisa Skubiak, EdD: Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Ann C. Childress, MD: Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV

Implementation of an intranasal esketamine service on an adult inpatient voluntary psychiatry unit

Megan Maroney PharmD, BCPP, FAAPP, Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey and Monmouth Medical Center, Long Branch, NJ; Laura Borque, MSN, RN, PMH-BC, NPD-BC Monmouth Medical Center, Long Branch, NJ

1 2 3 4 5